Checkpoint Targeting Bispecifics

The ICM-targeting bispecifics landscape has seen rapid and substantial growth in the past decade. An astonishing 648 trials have been initiated since 2012, reflecting an average annual growth rate of 188% in drugs entering the clinic! As expansion continues, fueled by better patient recruitment and increased investment, we are witnessing quicker phase progression and a more diverse disease landscape.

Two highly promising assets are set to submit BLA/NDA applications soon, and with one drug already approved in China, it will be interesting to see which checkpoint-targeting bispecific becomes the first to be approved in the global market.